Sangamo Therapeutics (NASDAQ: SGMO) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Sangamo Therapeutics to similar businesses based on the strength of its earnings, institutional ownership, analyst recommendations, risk, profitability, dividends and valuation.
Earnings & Valuation
This table compares Sangamo Therapeutics and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Sangamo Therapeutics||$19.39 million||-$71.65 million||-24.93|
|Sangamo Therapeutics Competitors||$284.28 million||$34.29 million||133.68|
Sangamo Therapeutics’ rivals have higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a summary of recent ratings and target prices for Sangamo Therapeutics and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Sangamo Therapeutics Competitors||848||3197||11597||230||2.71|
Sangamo Therapeutics currently has a consensus target price of $18.60, suggesting a potential upside of 8.14%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 45.97%. Given Sangamo Therapeutics’ rivals higher possible upside, analysts clearly believe Sangamo Therapeutics has less favorable growth aspects than its rivals.
Institutional & Insider Ownership
64.4% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 5.5% of Sangamo Therapeutics shares are held by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This table compares Sangamo Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Sangamo Therapeutics Competitors||-5,307.18%||-436.07%||-40.07%|
Volatility and Risk
Sangamo Therapeutics has a beta of 3.15, suggesting that its stock price is 215% more volatile than the S&P 500. Comparatively, Sangamo Therapeutics’ rivals have a beta of 0.55, suggesting that their average stock price is 45% less volatile than the S&P 500.
Sangamo Therapeutics beats its rivals on 7 of the 12 factors compared.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company’s product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.
Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.